미나세유카<- 바로가기 COURBEVOIE, FRANCE & OSLO, NORWAY--( / ) October 07, 2019 -- IDEMIA, the global leader in Augmented Identity announces that IDEMIA and IDEX Biometrics ASA, the leading provider of advanced fingerprint identification and authentication solutions have entered a worldwide license agreement for use of IDEX’s biometric enrollment intellectual property. Under the terms of the agreement, IDEX has granted IDEMIA a license to use some IDEX patents in order to develop, manufacture and sell on-card enrollment devices while benefiting from IDEMIA’s biometric card software expertise.
“On-card Enrollment” refers to enabling a user to enroll onto a brand new biometric smart card in their own home. The cardholder may receive a new biometric smart card and a lightweight receptacle containing a power source through the mail. The user then inserts the card into the enrollment receptacle and simply touches the fingerprint sensor area on the card several times. Throughout the enrollment process, the card is not connected to any other device or network. With no need to visit a bank, no need to involve another device, no apps, no wireless pairing and no compatibility problems for the user to worry about, on-card enrollment is a cost-effective, practical solution that is championing over alternative connected enrollment methods.
IDEMIA's intelligent services provide financial institutions and individuals with a range of solutions to meet the ever-increasing need for security and payment flow. It is by incorporating biometric technology into payment methods that IDEMIA is able to improve the customer experience. IDEMIA is investing into biometric cards as the obvious answer to the growing consumer needs for ever more security and convience while paying with their cards. IDEMIA is the first company to have obtained an international scheme certificate for a biometric card and is providing an industry-leading product roadmap, combining own and licensed technology for enrollment.
Earlier this year, IDEX was granted foundational patents for devices and methods relating to on-card enrollment on biometric smart cards by the United States Patent and Trademark Office and IP Australia. IDEX also has additional patent applications for its enrollment inventions pending in other major territories. These patents form part of a broad portfolio of patents and applications on fingerprint sensor and biometric algorithm technology, which IDEX intends to use to enable the expansion of the biometric smart card and payment card markets.
Today's announcement deepens a long-standing collaboration between IDEMIA and IDEX, in order to develop biometric smart cards that can be supported by IDEX’s on-card fingerprint enrollment patents, another step towards democratizing biometric security.
Dave Orme, SVP of Sales and Marketing at IDEX comments: “IDEX Biometrics started filing its first patent applications for on-card enrollment concepts in 2017. Since then, this disruptive invention has grown in popularity throughout the payment industry and represents a key enabler for biometric smart card adoption. We’re delighted to be licensing this unique and innovative solution to IDEMIA as we continue to work closely together to enable mass adoption of biometric smart cards.”
Amanda Gourbault, Executive VP of the Financial Institutions Business Unit at IDEMIA: “Our expertise and technology at IDEMIA make possible to offer secure payment methods and to respond to customers’ growing demand for biometric authentication. Using biometrics to secure point of sale transactions reduces friction in the payment experience as well as providing the best security to carry out transactions with complete trust.”
About IDEX Biometrics
IDEX Biometrics ASA (OSE: IDEX), is the leading provider of fingerprint identification technologies offering simple, secure and personal authentication for all. We help people make payments, prove their identity, gain access to information, unlock devices or gain admittance to buildings with the touch of a finger. We invent, engineer and commercialize these secure, yet incredibly user-friendly solutions. Our total addressable market represents a fast-growing multi-billion-unit opportunity.
For more information, visit and follow @IDEXBiometrics
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets - our identity - whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With 13,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit / Follow @IdemiaGroup on Twitter
View source version on businesswire.com:IDEMIA enters patent license agreement for on-card enrollment solutions with IDEX in order to expand its leadership in the field of biometric cards
INGELHEIM, GERMANY & INDIANAPOLIS, 클럽 아우디녀 소유 US--( / ) June 11, 2019 -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a new post-hoc analysis of data from the EMPA-REG OUTCOME® trial. These results indicated that the effect of empagliflozin on reducing cardiovascular and renal risk was consistent between a sub-group of adults with type 2 diabetes and established cardiovascular disease, who also have a form of chronic kidney disease without overt proteinuria (high levels of protein in the urine), and all others in the trial.[1] The results were shared as an oral presentation at the 79th American Diabetes Association (ADA) Scientific Sessions® on 10 June in San Francisco, California, US.
“We 클럽 아우디녀 스코어888 are pleased to share new research data from the landmark EMPA-REG OUTCOME® trial, examining the effects of empagliflozin in adults with type 2 diabetes who have an increasingly common, yet infrequently studied, form of chronic kidney disease,” 클럽 아우디녀 said Waheed Jamal, MD, Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim. “The results support the need for additional studies aimed at addressing important unmet medical needs for people with various forms of kidney disease. To that end, we have initiated a large outcomes 클럽 아우디녀 티티알바 trial, EMPA-KIDNEY, to investigate the effects of empagliflozin on cardiovascular death and the progression of kidney disease in a broad population of adults with chronic kidney disease.”
Globally, more than 500 million people are affected by chronic 클럽 아우디녀 부르르닷컴 kidney disease, up to 40 percent of whom have diabetes.[2,3,4] Chronic kidney disease is typically accompanied by 클럽 아우디녀 the presence of varying amounts of protein in the urine, known as proteinuria.[5] The majority of 아우디녀 Globally,with chronic kidney disease, 미나세유카 비아샵 however, have normal to moderately-increased urinary protein levels, rather than overt proteinuria.[5] Kidney disease without overt proteinuria is becoming more common yet is rarely studied in clinical trials, despite the known increased risk for adverse outcomes.[5]
In this new post-hoc analysis, the effect of empagliflozin on reducing 클럽 아우디녀 Inrisk of cardiovascular and kidney outcomes was consistent between people in the EMPA-REG OUTCOME® 클럽 아우디녀 오토렌트 trial who had chronic kidney disease without overt proteinuria and all others in 클럽 아우디녀 the trial.[1] Outcomes examined included cardiovascular death, hospitalisation for heart failure, new or worsening kidney disease, and the combination of cardiovascular death or 미나세유카 porno hospitalisation for heart failure, as well as safety outcomes of interest.[1]
Furthermore, results from a separate post-hoc analysis recently presented at the ISN World Congress of Nephrology 2019, indicated that the effect of empagliflozin on 클럽 아우디녀 penis the cardiorenal outcome*, was consistent between people in the EMPA-REG OUTCOME® trial who had proteinuric kidney disease and all others in the trial. Together, these post-hoc analyses suggest that 클럽 아우디녀 bra the effect of empagliflozin on cardiorenal outcomes is consistent regardless of whether patients 미나세유카 pornvideo have proteinuric kidney disease or not.
“These new findings are just one part of a broad and comprehensive clinical development programme that explores how empagliflozin can 클럽 아우디녀 sbs강심장 improve patient health outcomes and 클럽 아우디녀 허각강심장 fill therapeutic gaps to serve as a broad cardiometabolic treatment option,” said Sherry Martin, MD, Vice President, Medical Affairs, Lilly. “We look forward to gathering additional information through results from EMPA-KIDNEY, which will examine the potential for empagliflozin to improve outcomes for people with chronic kidney disease, including those with and without proteinuria.”
EMPA-KIDNEY will enrol approximately 5,000 adults with chronic 클럽 아우디녀 kidney disease both with and without diabetes as well as with and without proteinuria worldwide.[6]
*Defined 클럽 아우디녀 일본성인사이트 미나세유카 일본성인사이트 as end-stage kidney disease (initiation of maintenance renal replacement therapy or sustained eGFR <15 ml/min/1.73m2), sustained doubling or creatinine, or renal/cardiovascular death.
About EMPA-KIDNEY: The study 미나세유카 승승장구우영태연 of heart and 클럽 아우디녀 kidney protection with 클럽 아우디녀 empagliflozin[6] 클럽 아우디녀 쎅스코리아
EMPA-KIDNEY (NCT03594110) is a multinational randomised, double-blind, placebo-controlled 클럽 아우디녀 동방신기우결 clinical trial, designed to evaluate the effect of empagliflozin on clinically relevant outcomes: kidney disease progression and cardiovascular mortality risk. The primary outcome is defined as time to a first event of either a cardiovascular death or kidney disease progression, defined as end-stage kidney disease (the need for kidney replacement therapy such as, dialysis or kidney transplantation), a sustained decline in eGFR to <10mL/min/1.73m2, renal death or a sustained decline of ≥40 percent in eGFR from randomisation. EMPA-KIDNEY includes people with established chronic kidney disease both with and without diabetes, receiving either empagliflozin 10 mg or placebo, on top of current standard of care.
EMPA-KIDNEY is an academic collaboration, independently 클럽 아우디녀 conducted, analysed and reported by the Medical Research Council Population Health Research Unit at the University 미나세유카 최은정컵 of Oxford (MRC PHRU), which is based in the Clinical Trial 고고TV EMPA-KIDNEYUnit and Epidemiological Studies Unit (CTSU). Boehringer Ingelheim and Lilly are providing the funding for the study as part of their commitment to advancing treatments and pioneering research to address the public health challenges of cardiovascular, metabolic and kidney diseases beyond type 2 diabetes.
About 클럽 아우디녀 아테나엄상미 Chronic 스타픽 AboutDisease
Chronic kidney disease is defined as a progressive decline of kidney function over time. About two thirds of chronic kidney disease cases are attributable 미나세유카 아프리카티비엄상미 to metabolic conditions 클럽 아우디녀 such as diabetes (known as diabetic kidney disease), obesity and hypertension.[7,8,9]
Notably, chronic kidney disease is associated with increased morbidity and mortality. The majority of deaths among people with chronic kidney disease occur as a result of cardiovascular complications, often before reaching end-stage kidney disease.[10,11,12] Once end-stage kidney disease is reached, affected individuals have to undergo kidney replacement treatments, such as chronic dialysis or kidney transplantation.[13] Chronic kidney disease is highly prevalent in various parts of the world, affecting more than 10 percent of the population.[14] Since there is currently no approved treatment available to specifically reduce kidney disease progression and cardiovascular death, the overarching unmet medical need for new treatment options in people 클럽 아우디녀 미니매직기 with chronic kidney disease is evident. 미나세유카 매직기
About 클럽 아우디녀 Saintphotolife About미나세유카 무료성인영화
Empagliflozin (marketed as Jardiance®) is an oral, once daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine 클럽 아우디녀 to include cardiovascular death risk reduction data in the label in several countries.[15,16,17]
Inhibition of SGLT2 with empagliflozin in people with type 2 diabetes and high blood sugar levels leads 미나세유카 무료섹스사이트 to excretion of excess sugar in the urine. In addition, initiation of empagliflozin increases excretion of salt from the body and reduces the fluid load of the body’s blood vessel system (i.e. intravascular volume). 클럽 아우디녀 Empagliflozin induces changes to the sugar, salt and water metabolism in the body that may contribute to the reductions in cardiovascular death observed in the EMPA-REG OUTCOME® trial.
Please 클럽 아우디녀 click on the 클럽 아우디녀 following link for ‘Notes to Editors’ 미나세유카 야동보는법 and ‘References’:
View source version 미나세유카 야동주소 on businesswire.com:Korea Newswire 클럽 아우디녀 섹스하는법 distributes your news across every media 클럽 아우디녀 유이청순글래머 channels through the industry’s largest press release distribution network
